/
Metabolic & Endocrine
Non-Alcoholic Steatohepatitis
12
Pipeline Programs↗
14
Active Trials↗
38
Companies Involved↗
Non-Alcoholic Steatohepatitis is an emerging landscape with 12 programs across 38 companies. The most active players are Akero Therapeutics, Cascade Pharmaceuticals, Inc, Sinew Pharma Inc.. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 11
Phase 24
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
10 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
91
clinical trials
Completed57 · 63%
Terminated9 · 10%
Recruiting8 · 9%
Unknown status8 · 9%
Active, not recruiting4 · 4%
Withdrawn3 · 3%
Other2 · 2%
Clinical Trials
Trial Activity
91 trials
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
Recruiting·—·N/A·NCT06193629·150 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)